Oregon is currently home to 1216 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
Recruiting
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Legacy Good Samaritan Medical Center-Gynecological Oncology Group, Portland, Oregon
Conditions: Cervical Cancer
Register for Updates
Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation
NCT04897256
Recruiting
The goal of this intervention is to explore the effectiveness of a Turning Intervention (TURN-IT) to improve quality of turning in participants with Parkinson's Disease (PD). An unique exercise program has been developed - TURN-IT - in which participants practice exercises that focus on physiological constraints that impair turning ability, such as axial rigidity, narrow base of support, bradykinesia, and inflexible set-shifting. The 60 participants with PD and a history of falls in the previous... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
12/13/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Parkinson Disease
Register for Updates
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505
Recruiting
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to ev... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Oncology Associates of Oregon, Eugene, Oregon
Conditions: Small Cell Lung Cancer
Register for Updates
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814
Recruiting
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
Gender:
MALE
Ages:
Between 4 years and 14 years
Trial Updated:
12/12/2024
Locations: Shriners Children's Portland, Portland, Oregon
Conditions: Duchenne Muscular Dystrophy
Register for Updates
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264
Recruiting
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, β-catenin, Beta-catenin, Adenomatous Polyposis Coli, APC, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, FAP, Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, CTNNB1, Adamantinomatous Craniopharyngioma
Register for Updates
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
NCT04496687
Recruiting
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Providence, Portland, Oregon
Conditions: Spontaneous Coronary Artery Dissection
Register for Updates
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
NCT03511118
Recruiting
Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying. We are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the amount of drug that is transferred to breastmilk and estimate how much of drug that is consumed by bre... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/12/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: OHSU Doernbecher Children's Hospital, Portland, Oregon
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
NCT06320405
Recruiting
This phase I/II trial tests the safety, side effects, and effectiveness of axatilimab in combination with retifanlimab and paclitaxel for the treatment of patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Axatilimab is a monoclonal antibody that may interfere with the ability of tumor cells to gro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates
Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT05320198
Recruiting
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
Register for Updates
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/09/2024
Locations: Multiple Sclerosis Center, Oregon Health & Science University, Portland, Oregon
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates